MoonLake Immunotherapeutics (MLTX) Invested Capital (2021)

MoonLake Immunotherapeutics (MLTX) posted quarterly Invested Capital of $15.0 million for Q4 2021.

MoonLake Immunotherapeutics (MLTX) Invested Capital (2021) Analysis & Trends

MoonLake Immunotherapeutics' Invested Capital history runs 1 years deep, the most recent figure standing at $15.0 million for Q4 2021.

  • In Q4 2021, Invested Capital changed N/A year-over-year to $15.0 million; the TTM figure through Sep 2022 stood at $15.0 million (changed N/A YoY), while the FY2021 annual figure was $15.0 million, changed N/A from the prior year.
  • Invested Capital for Q4 2021 stood at $15.0 million.
  • The five-year high for Invested Capital was $15.0 million in Q4 2021, with the low at $15.0 million in Q4 2021.

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Invested Cap. (Qtr)
1 Vertex Pharmaceuticals 128.13 Bn 120.28 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 112.33 Bn 104.33 Bn 3.93 Bn -
3 Argenx Se 53.24 Bn 48.05 Bn 1.41 Bn -
4 Revolution Medicines 43.64 Bn 43.64 Bn - -
5 BeOne Medicines 39.27 Bn 34.17 Bn 1.53 Bn 190.90 Mn
6 MindWalk Holdings 35.32 Bn 35.31 Bn 1.82 Bn 2.57 Mn
7 Royalty Pharma 33.72 Bn 35.84 Bn - 380.00 Mn
8 Alnylam Pharmaceuticals 30.58 Bn 27.27 Bn 992.69 Mn -
9 Insmed 27.01 Bn 25.85 Bn 358.27 Mn -
10 MoonLake Immunotherapeutics 1.40 Bn 864.68 Mn - -

Historic Data

Download Data
DateValue
Dec 31, 2021 15.00 Mn